Advanced search
Publication Cover
Future Oncology Volume 11, 2015 - Issue 1
Submit an article Journal homepage
7,348
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Michael Hallek1 Department I of Internal Medicine & Center of Integrated Oncology, University of Cologne, GermanyCorrespondence[email protected]
,
Neil E Kay2 Mayo Clinic, Rochester, MN, USA
,
Anders Osterborg3 Department of Hematology, Karolinska University Hospital, Solna, Stockholm, Sweden
,
Asher A Chanan-Khan4 Mayo Clinic, Jacksonville, FL, USA
,
Michelle Mahler5 Janssen Research & Development, Raritan, NJ, USA
,
Mariya Salman5 Janssen Research & Development, Raritan, NJ, USA
,
Ying Wan5 Janssen Research & Development, Raritan, NJ, USA
,
Steven Sun5 Janssen Research & Development, Raritan, NJ, USA
,
Sen Hong Zhuang5 Janssen Research & Development, Raritan, NJ, USA
&
Angela Howes6 Janssen Research & Development, High Wycombe, UK
 show all
Pages 51-59 | Published online: 05 Jun 2014

Figures & data

Figure 1. Study design schema.

†A cycle will be defined as 28 days, except for cycle 1, which will be 29 days.

IV: Intravenous.

Figure 1. Study design schema. †A cycle will be defined as 28 days, except for cycle 1, which will be 29 days.IV: Intravenous.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.